Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Dass

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Drug Delivery|September 16, 2000
Apolipoprotein A-I, phospholipid vesicles, and cyclodextrins as potential anti-atherosclerotic drugs: delivery, pharmacokinetics, and efficacyC R Dass
Journal of Cancer Research and Clinical Oncology|April 6, 2002
Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancerC R Dass
The Journal of Pharmacy and Pharmacology|August 10, 2000
Apolipoprotein A-I, cyclodextrins and liposomes as potential drugs for the reversal of atherosclerosis. A reviewC R Dass, W Jessup
Die Pharmazie|January 26, 2013
Reduction in tumour cell invasion by pigment epithelium-derived factor is mediated by membrane type-1 matrix metalloproteinase downregulationG Filiz, C R Dass
Drug Delivery|January 5, 2002
Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from genotherapyC R Dass, T Su
The Journal of Pharmacy and Pharmacology|February 24, 2001
Delivery of lipoplexes for genotherapy of solid tumours: role of vascular endothelial cellsC R Dass, T Su
Die Pharmazie|May 24, 2016
Potential of pigment epithelium-derived factor (PEDF) as a bone regenerative biopharmaceuticalP X Lee, C R Dass
The Journal of Pharmacy and Pharmacology|September 1, 1999
Lipoplexes and tumours. A reviewC R Dass, M A Burton
Die Pharmazie|July 9, 2008
C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologiesC R Dass, P F M Choong
Die Pharmazie|February 15, 2008
Pigment epithelium-derived factor (PEDF): drug developmental challenges ahead for a budding anti-angiogenicC R Dass, P F M Choong
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Drug Delivery|September 16, 2000
Apolipoprotein A-I, phospholipid vesicles, and cyclodextrins as potential anti-atherosclerotic drugs: delivery, pharmacokinetics, and efficacyC R Dass
Journal of Cancer Research and Clinical Oncology|April 6, 2002
Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancerC R Dass
The Journal of Pharmacy and Pharmacology|August 10, 2000
Apolipoprotein A-I, cyclodextrins and liposomes as potential drugs for the reversal of atherosclerosis. A reviewC R Dass, W Jessup
Die Pharmazie|January 26, 2013
Reduction in tumour cell invasion by pigment epithelium-derived factor is mediated by membrane type-1 matrix metalloproteinase downregulationG Filiz, C R Dass
Drug Delivery|January 5, 2002
Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from genotherapyC R Dass, T Su
The Journal of Pharmacy and Pharmacology|February 24, 2001
Delivery of lipoplexes for genotherapy of solid tumours: role of vascular endothelial cellsC R Dass, T Su
Die Pharmazie|May 24, 2016
Potential of pigment epithelium-derived factor (PEDF) as a bone regenerative biopharmaceuticalP X Lee, C R Dass
The Journal of Pharmacy and Pharmacology|September 1, 1999
Lipoplexes and tumours. A reviewC R Dass, M A Burton
Die Pharmazie|July 9, 2008
C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologiesC R Dass, P F M Choong
Die Pharmazie|February 15, 2008
Pigment epithelium-derived factor (PEDF): drug developmental challenges ahead for a budding anti-angiogenicC R Dass, P F M Choong
Pageof 3